Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company
Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company

Financial Statements

  Year Ending Dec 2017 (Update) Year Ending Dec 2016 (Update) Year Ending Dec 2015 (Reclassified) Year Ending Dec 2014 (Update)
Cash & Equivalents 227.32 158.22 139.74 129.94
Short Term Investments 0.25 0.25 0.25 3.31
Cash and Short Term Investments 227.57 158.47 139.99 133.25
Accounts Receivable - Trade, Gross 32.33 39.87 30.50 70.88
Provision for Doubtful Accounts -0.07 -0.09 -0.12 -0.12
Accounts Receivable - Trade, Net 32.26 39.78 30.38 70.76
Notes Receivable - Short Term 0.00 0.00 2.22 0.00
Receivables - Other 2.13 5.75 10.36 5.49
Total Receivables, Net 34.39 45.54 42.96 76.25
Inventories - Finished Goods 5.19 2.31 1.50 3.71
Inventories - Work In Progress 2.55 7.84 4.23 3.98
Inventories - Raw Materials 1.08 2.99 1.61 1.51
Inventories - Other -3.10 -4.42 -3.16 0.00
LIFO Reserve 0.00 0.00 0.00 0.00
Total Inventory 5.72 8.72 4.18 9.20
Prepaid Expenses 10.07 3.93 3.51 3.77
Deferred Income Tax - Current Asset 0.00 0.00 0.00 0.00
Other Current Assets, Total 0.00 0.00 0.00 0.00
Total Current Assets 277.75 216.65 190.63 222.47
Buildings - Gross 2.94 2.91 2.87 2.85
Machinery/Equipment - Gross 3.62 3.17 4.39 4.26
Other Property/Plant/Equipment - Gross 0.22 0.21 0.36 0.34
Property/Plant/Equipment, Total - Gross 6.78 6.30 7.62 7.45
Accumulated Depreciation, Total -6.19 -5.85 -6.70 -6.05
Property/Plant/Equipment, Total - Net 0.59 0.45 0.92 1.41
Goodwill, Net 18.16 17.89 17.96 18.20
Intangibles - Gross 305.67 305.67 305.67 305.67
Accumulated Intangible Amortization -168.51 -141.43 -115.33 -75.57
Intangibles, Net 137.16 164.23 190.34 230.10
LT Investment - Affiliate Companies 37.53 11.53 5.19 8.50
LT Investments - Other 0.00 0.00 0.00 0.00
Long Term Investments 37.53 11.53 5.19 8.50
Note Receivable - Long Term 0.67 0.00 0.00 0.00
Deferred Charges 0.00 0.00 0.00 2.17
Deferred Income Tax - Long Term Asset 0.00 0.00 0.00 0.00
Other Long Term Assets 15.59 18.02 14.02 7.19
Other Long Term Assets, Total 15.59 18.02 14.02 9.36
Total Assets 487.44 428.77 419.05 490.03
Accounts Payable 33.65 30.49 26.68 8.99
Payable/Accrued 0.30 0.38 1.06 3.22
Accrued Expenses 25.90 26.28 33.09 74.94
Notes Payable/Short Term Debt 38.22 0.00 0.00 0.00
Customer Advances 3.87 3.19 6.13 9.96
Other Payables 7.54 4.32 3.89 6.29
Other Current Liabilities 0.28 0.86 5.49 6.04
Other Current liabilities, Total 11.69 8.37 15.51 22.29
Total Current Liabilities 109.75 65.51 76.34 109.44
Long Term Debt 0.00 97.04 99.38 96.30
Capital Lease Obligations 0.00 0.00 0.00 0.00
Total Long Term Debt 0.00 97.04 99.38 96.30
Total Debt 38.22 97.04 99.38 96.30
Deferred Income Tax - Long Term Liability 1.44 6.68 6.78 6.57
Deferred Income Tax 1.44 6.68 6.78 6.57
Minority Interest 0.00 0.00 0.00 0.00
Other Long Term Liabilities 24.91 23.51 23.69 23.17
Other Liabilities, Total 24.91 23.51 23.69 23.17
Total Liabilities 136.10 192.74 206.19 235.48
Redeemable Convertible Preferred Stock 0.00 0.00 0.12 0.00
Redeemable Preferred Stock, Total 0.00 0.00 0.12 0.00
Preferred Stock - Non Redeemable 0.00 0.00 0.00 0.12
Convertible Preferred Stock – Non-Redeemable 0.00 0.00 0.00 0.00
Preferred Stock - Non Redeemable, Net 0.00 0.00 0.00 0.12
Common Stock 0.10 0.08 0.07 0.07
Common Stock, Total 0.10 0.08 0.07 0.07
Additional Paid-In Capital 837.35 640.17 552.11 538.55
Retained Earnings (Accumulated Deficit) -502.11 -402.64 -334.12 -283.34
Treasury Stock - Common 0.00 0.00 0.00 0.00
Other Comprehensive Income 16.00 -1.58 -5.32 -0.85
Other Equity, Total 16.00 -1.58 -5.32 -0.85
Total Equity 351.34 236.03 212.86 254.55
Total Liabilities & Shareholders' Equity 487.44 428.77 419.05 490.03
Shares Outstanding – Common Stock Primary Issue 100.74 80.47 68.23 65.97
Total Common Shares Outstanding 100.74 80.47 68.23 65.97
Treasury Shares – Common Primary Issue 0.00 0.00 0.00 0.00
Shares Outstanding - Preferred Issue 3 0.00 0.00 0.00 0.00
Total Preferred Shares Outstanding 0.00 0.00 0.00 0.00
Treasury Shares - Preferred Issue 3 0.00 0.00 0.00 0.00
Employees 215.00 227.00 212.00 241.00
Number of Common Shareholders 361.00 411.00 418.00 396.00
Accumulated Intangible Amortization 168.51 141.43 115.33 75.57
Deferred Revenue - Current 3.87 3.19 6.13 9.96
Deferred Revenue - Long Term 0.37 0.49 0.63 0.00
Total Current Assets less Inventory 272.03 207.94 186.45 213.27
Quick Ratio 2.48 3.17 2.44 1.95
Current Ratio 2.53 3.31 2.50 2.03
Net Debt -189.35 -61.43 -40.49 -36.83
Tangible Book Value 196.02 53.91 4.44 6.14
Tangible Book Value per Share 1.95 0.67 0.07 0.09
Total Long Term Debt, Supplemental 41.63 115.96 129.75 133.05
Long Term Debt Maturing within 1 Year 41.63 3.03 3.30 3.30
Long Term Debt Maturing in Year 2 0.00 56.46 63.23 3.30
Long Term Debt Maturing in Year 3 0.00 56.46 63.23 3.30
Long Term Debt Maturing in Year 4 0.00 0.00 0.00 61.58
Long Term Debt Maturing in Year 5 0.00 0.00 0.00 61.58
Long Term Debt Maturing in 2-3 Years 0.00 112.93 126.45 6.60
Long Term Debt Maturing in 4-5 Years 0.00 0.00 0.00 123.15
Long Term Debt Maturing in Year 6 & Beyond 0.00 0.00 0.00 0.00
Total Capital Leases 0.00 0.00 0.00 0.00
Capital Lease Payments Due in Year 1 0.00 0.00 0.00 0.00
Capital Lease Payments Due in Year 2 0.00 0.00 0.00 0.00
Capital Lease Payments Due in Year 3 0.00 0.00 0.00 0.00
Capital Lease Payments Due in Year 4 0.00 0.00 0.00 0.00
Capital Lease Payments Due in Year 5 0.00 0.00 0.00 0.00
Capital Lease Payments Due in 2-3 Years 0.00 0.00 0.00 0.00
Capital Lease Payments Due in 4-5 Years 0.00 0.00 0.00 0.00
Capital Lease Payments Due in Year 6 & Beyond 0.00 0.00 0.00 0.00
Total Operating Leases 1.86 2.84 0.00 5.10
Operating Lease Payments Due in Year 1 1.31 1.17 0.00 1.21
Operating Lease Payments Due in Year 2 0.55 1.21 0.00 1.15
Operating Lease Payments Due in Year 3 0.00 0.46 0.00 1.12
Operating Lease Payments Due in Year 4 0.00 0.00 0.00 1.16
Operating Lease Payments Due in Year 5 0.00 0.00 0.00 0.46
Operating Lease Payments Due in 2-3 Years 0.55 1.67 0.00 2.27
Operating Lease Payments Due in 4-5 Years 0.00 0.00 0.00 1.62
Standardized Operating Lease Payments Due in Year 6 and Beyond 0.00 0.00 0.00 0.00
Number of Products in Phase I 0.00 0.00 2.00 0.00
Number of Products in Phase II 1.00 1.00 2.00 2.00
Number of Products in Phase III 2.00 1.00 1.00 1.00

In millions of USD (except for per share items)

Back to top

Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company

Copyright Nasdaq. Minimum 15 minutes delayed.